Your session is about to expire
← Back to Search
Gardasil9 Vaccine for Human Papillomavirus
Study Summary
This trial will explore whether a two-dose regimen of the 9-valent HPV vaccine is effective in providing immunity against the virus. The trial will last for four years, with participants receiving the vaccine doses at months 0 and 12.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My child is between 4 and 8 years old.I have never received the HPV vaccine.I have a weakened immune system or have been on drugs that lower my immunity.I have a blood clotting disorder or low platelet count.
- Group 1: Single Arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there an open enrollment period for this experiment?
"Yes, there is evidence on clinicaltrials.gov that this medical research study, which was originally listed on September 26th 2022, is actively enrolling participants. 150 volunteers need to be procured from 1 participating institution."
Does this clinical trial enroll adults above the age of 45?
"Participants must be between 4 and 8 years of age to meet the enrollment criterion. In addition, there are 19 trials for patients below majority and 54 studies involving individuals older than 65."
What goal is this experiment attempting to reach?
"According to Merck Sharp & Dohme LLC, the main evaluation criterion of this trial will be HPV31 antibodies at 13 months. This metric will be monitored and assessed over a 60 month time period. Also, secondary outcomes such as injection site swelling severity and redness after both initial and second injections shall also be tracked on a scale from 0-4 (0 being no symptoms while 4 is severe)."
What is the current enrollment count for this trial?
"Affirmatively, the information hosted on clinicaltrials.gov confirms that this medical study is actively enrolling patients; it was initially announced on September 26th 2022 and has been amended as recently as October 1st of the same year. The team needs to recruit 150 individuals from a single site."
What criteria must potential participants meet to join this research initiative?
"This research project is accepting 150 young patients aged 4-8 years old, who have been diagnosed with human papillomavirus. For entry into this study, enrollees must also meet the criteria of having a medical record at Boston Medical Centre or one of its affiliated Community Health Centers and not previously receiving HPV Vaccination."
Share this study with friends
Copy Link
Messenger